Collegium Pharmaceutical Inc.
Organization details
- Legal name
- Collegium Pharmaceutical Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Virginia
- Headquarters city
- Stoughton
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- COLL
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001267565
Board of directors
-
Carlos Paya V · DirectorSince 2025
-
Donovan Michael Glancy · DirectorSince 2026
-
Garen G. Bohlin · DirectorSince 2023
-
Gino Santini · DirectorSince 2023
-
Gwen A. Melincoff · DirectorSince 2023
-
John A. Fallon · DirectorSince 2023
-
John Gordon Freund · DirectorSince 2023
-
Joseph Ciaffoni · Director · President and CEOSince 2023
- Since 2023
-
Nancy Lurker · DirectorSince 2025
-
Neil F. McFarlane · DirectorSince 2023
-
Rita J. Balice-Gordon · DirectorSince 2023
-
Vikram Karnani · Director · President and CEOSince 2024
Chief executives
Outstanding · grade A+
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 35% of the scoring weight is on file.
- Revenue growth 20%
- 95
- Earnings growth 15%
- 88
17.4% a year in revenue
15.8% a year in earnings per share
35% of the scoring weight is on file. Figures cover December 2023 – December 2025.
Director election results
Annual meeting of May 14, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
95.1%
-
97.4%
-
97.8%
-
98.1%
-
99.1%
-
99.4%
-
99.9%
Board connections
10 of this board's directors also sit on 18 other boards. 17 are in the same sector.
-
Alkermes plc Same sectorvia Nancy Lurker
-
Avalo Therapeutics Inc. Same sectorvia Michael Thomas Heffernan
-
Biohaven Ltd. Same sectorvia Michael Thomas Heffernan
-
COMPASS Pathways Plc Same sectorvia Gino Santini
- via Gwen A. Melincoff
-
Dyne Therapeutics Inc. Same sectorvia Vikram Karnani
- via Nancy Lurker
-
Gain Therapeutics Inc. Same sectorvia Gwen A. Melincoff
-
Indivior Pharmaceuticals Inc. Same sectorvia Joseph Ciaffoni
-
Karyopharm Therapeutics Inc. Same sectorvia Garen G. Bohlin
-
Protalix BioTherapeutics Inc. (DE) Same sectorvia Gwen A. Melincoff
-
SI-BONE Inc. Same sectorvia John Gordon Freund
-
Standard BioTools Inc. Same sectorvia Carlos Paya V
-
Sutro Biopharma Inc. Same sectorvia John Gordon Freund
-
Trevi Therapeutics Inc. Same sectorvia Michael Thomas Heffernan
-
Vaxcyte Inc. Same sectorvia Carlos Paya V
-
Zevra Therapeutics Inc. Same sectorvia Neil F. McFarlane
-
enGene Therapeutics Inc. Same sectorvia Michael Thomas Heffernan
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $6,028,903
- 12 sales by 7 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 8, 2026 | Gino Santini Director | Option exercise | +8,700 | $16.49 | $143,463 |
| May 18, 2026 | John Gordon Freund Director | Open-market sale | −20 | $34.05 | $681 |
| May 15, 2026 | John Gordon Freund Director | Option exercise | +8,700 | $16.49 | $143,463 |
| May 15, 2026 | John Gordon Freund Director | Open-market sale | −4,127 | $34.54 | $142,547 |
| May 14, 2026 | Donovan Michael Glancy Director | Grant or award | +17,482 | — | — |
| May 14, 2026 | Nancy Lurker Director | Grant or award | +8,741 | — | — |
| May 14, 2026 | Carlos Paya V Director | Grant or award | +8,741 | — | — |
| May 14, 2026 | John Gordon Freund Director | Grant or award | +8,741 | — | — |
| May 14, 2026 | Garen G. Bohlin Director | Grant or award | +8,741 | — | — |
| May 14, 2026 | Rita J. Balice-Gordon Director | Grant or award | +8,741 | — | — |
| May 14, 2026 | Gino Santini Director | Grant or award | +8,741 | — | — |
| May 13, 2026 | Nancy Lurker Director | Open-market sale | −4,500 | $35.97 | $161,865 |
| May 11, 2026 | Garen G. Bohlin Director | Option exercise | +8,700 | $16.49 | $143,463 |
| May 11, 2026 | Garen G. Bohlin Director | Open-market sale | −8,700 | $37.18 | $323,466 |
| Mar 18, 2026 | Dieter David Officer (EVP & General Counsel) | Open-market sale | −13,976 | $34.92 | $488,042 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Collegium Pharmaceutical Inc.
Who is the CEO of Collegium Pharmaceutical Inc.?
Vikram Karnani has been Collegium Pharmaceutical Inc.'s President and CEO since November 2024.
How many directors are on Collegium Pharmaceutical Inc.'s board?
Collegium Pharmaceutical Inc.'s board has 13 directors: Carlos Paya V, Donovan Michael Glancy, Garen G. Bohlin, Gino Santini, Gwen A. Melincoff, John A. Fallon, John Gordon Freund, Joseph Ciaffoni, Michael Thomas Heffernan, Nancy Lurker and 3 others.
Are Collegium Pharmaceutical Inc. insiders buying or selling shares?
Over the last 12 months, Collegium Pharmaceutical Inc. insiders made no open-market purchases and sold $6.0 million of shares in 12 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="collegium-pharmaceutical-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.